Small Cell Lung Cancer (SCLC) | Topics

 
FDA Grants Orphan Drug Designation to Toripalimab in ES-SCLC
April 25, 2022

The phase 3 JUPITER-08 trial assessed toripalimab plus chemotherapy, which was granted an orphan drug designation by the FDA, in patients with extensive-stage small cell lung cancer.

Adebrelimab Plus Chemotherapy Meets OS End Point in SCLC
April 13, 2022

A phase 3 trial of patients with extensive-stage small cell lung cancer who were treated with adebrelimab plus chemotherapy compared with matched placebo met the primary end point of overall survival.

Investigators Identify Markers Predictive of Durvalumab/Chemo Responses for ES-SCLC
April 11, 2022

Those with inflamed T cell or YAP1–positive extensive-stage small cell lung cancer were likely to gain an improvement in overall survival following treatment with durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Serplulimab Granted Orphan Drug Designation by FDA in SCLC
April 09, 2022

Serplulimab, which has been granted orphan drug designation by the FDA, is being considered as a treatment for patients with small cell lung cancer.

First-Line Tiragolumab Combo Misses PFS Co-Primary End Point in ES-SCLC
April 02, 2022

Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.

Oncology Peer Review On-The-Go: Future Directions in Small Cell Lung Cancer Treatment
December 22, 2021

In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.

Oncology Peer Review On-The-Go: Practical Considerations for Small Cell Lung Cancer Therapeutic Options
December 16, 2021

In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.

Phase 3 Study of First-Line Serplulimab/Chemotherapy Meets Primary End Point in ES-SCLC
December 09, 2021

Treatment with serplulimab yielded a significant improvement in overall survival in combination with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer.

WBRT Plus Radiation Boost Improves Survival Outcomes for Small Cell Lung Cancer With Brain Metastases
December 05, 2021

Compared with whole brain radiotherapy alone, the addition of local radiation boost to whole brain radiotherapy improved overall survival and progression-free survival among patients with small cell lung cancer and brain metastases.

Oncology Peer Review On-The-Go: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer
December 02, 2021

Wade Iams, MD, broke down some of the different treatment options, including lurbinectedin and topotecan, for patients with relapsed/refractory small cell lung cancer in the second episode of a 4-part small cell lung cancer podcast series.